CompanyGraph
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.31BCNY344.38M · vs all stocks (USD)
Revenue (TTM)
1.86BCNY278.06M · vs all stocks (USD)
Profit Margin
-2.52%Beta
0.2740xvs all stocks
52-Week Change
-31.52%vs all stocks
Market Capitalization
2.31BCNY344.38M · vs all stocks (USD)
Enterprise Value
2.16BCNY322.01M · vs all stocks (USD)
Forward P/E
21.53xPrice to Sales (TTM)
1.23xPrice to Book (MRQ)
1.19xEnterprise to Revenue
1.16xEnterprise to EBITDA
88.38xGross Margin
23.67%Profit Margin
-2.52%Operating Margin
-0.72%Return on Assets (TTM)
-1.24%Return on Equity (TTM)
-2.38%Revenue (TTM)
1.86BCNY278.06M · vs all stocks (USD)
Revenue per Share (TTM)
5.71CNYUpdated Sep 18, 2026Quarterly Revenue Growth
-18.90%Gross Profit (TTM)
406.09MCNY60.57M · vs all stocks (USD)
EBITDA (TTM)
165.59MCNY24.70M · vs all stocks (USD)
Net Income (TTM)
-46.97MCNY-7.01M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-58.70%Operating Cash Flow (TTM)
114.23MCNY17.04M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
11.32MCNY1.69M · vs all stocks (USD)
5-Year Average Dividend Yield
0.84%vs all stocks
Payout Ratio
0.00%Revenue
2.28BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
1.71BCNYFY2025 · Dec 31, 2025Gross Profit
567.48MCNYFY2025 · Dec 31, 2025Operating Income
14.26MCNY2.13M · vs all stocks (USD)
Pre-tax Income
36.19MCNYFY2025 · Dec 31, 2025Income Tax Expense
13.51MCNYFY2025 · Dec 31, 2025Net Income
22.68MCNYFY2025 · Dec 31, 2025EBIT
41.11MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
165.59MCNYFY2025 · Dec 31, 2025Research & Development
48.84MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
204.92MCNYFY2025 · Dec 31, 2025Other Operating Expenses
22.79MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
7.52MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
4.92MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0700CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
324.17MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
324.17MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
22.68MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
16.35KCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-119.57MCNYFY2025 · Dec 31, 2025Free Cash Flow
-305.34MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
409.91MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
22.68MCNYFY2025 · Dec 31, 2025Other Non-cash Items
14.71MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-192.79MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
35.84MCNYFY2025 · Dec 31, 2025Capital Expenditures
-185.77MCNYFY2025 · Dec 31, 2025Net Acquisitions
3.86MCNYFY2025 · Dec 31, 2025Sale of Investments
5.38MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-176.53MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
140.16MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-57.16MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-27.06MCNYFY2025 · Dec 31, 2025Other Financing Charges
-40.92MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
15.02MCNYFY2025 · Dec 31, 2025Shares Outstanding
334.12MSharesUpdated Sep 18, 2026Float Shares
250.71MSharesUpdated Sep 18, 2026% Held by Insiders
29.77%vs all stocks
% Held by Institutions
2.09%vs all stocks
Total Cash (MRQ)
458.67MCNY68.42M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.37CNYUpdated Sep 18, 2026Total Debt (MRQ)
315.41MCNY47.05M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1627xCurrent Ratio (MRQ)
1.73xBook Value per Share (MRQ)
5.80CNYUpdated Sep 18, 2026Total Assets
2.93BCNY436.78M · vs all stocks (USD)
Total Current Assets
1.33BCNYFY2025 · Dec 31, 2025Total Liabilities
953.10MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.60BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
262.95MCNYFY2025 · Dec 31, 2025Total Current Liabilities
690.15MCNYFY2025 · Dec 31, 2025Cash
409.91MCNYFY2025 · Dec 31, 2025Cash Equivalents
24.60MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
434.51MCNYFY2025 · Dec 31, 2025Accounts Receivable
320.38MCNYFY2025 · Dec 31, 2025Inventory
452.06MCNYFY2025 · Dec 31, 2025Accounts Payable
428.10MCNYFY2025 · Dec 31, 2025Short-term Debt
117.81MCNYFY2025 · Dec 31, 2025Other Current Liabilities
15.23MCNYFY2025 · Dec 31, 2025Long-term Debt
163.93MCNYFY2025 · Dec 31, 2025Common Stock (Book)
334.12MCNYFY2025 · Dec 31, 2025Retained Earnings
942.50MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.98BCNY294.62M · vs all stocks (USD)
52-Week Low
5.76CNYUpdated Sep 18, 202652-Week High
10.59CNYUpdated Sep 18, 202652-Week Change
-31.52%vs all stocks
Beta
0.2740xvs all stocks
50-Day MA
6.79CNYUpdated Sep 18, 2026200-Day MA
8.06CNYUpdated Sep 18, 2026Avg 10-Day Volume
4.93MSharesUpdated Sep 18, 2026Avg 30-Day Volume
6.19MSharesUpdated Sep 18, 2026Diluted EPS (TTM)
-0.1400CNYUpdated Sep 18, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -2.19
Altman Z-Score 2.99: safe zoneNotable
Altman Z-Score: 2.99
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Jilin Jian Yisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Ocugen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Enanta Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Surrozen, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu GDK Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shoulder Innovations, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule